Passa al contenuto
Merck

F0700000

Furosemide

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid, 5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

100 MG

183,00 €

183,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine in blocco

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C12H11ClN2O5S
Numero CAS:
Peso molecolare:
330.74
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Nome del prodotto

Furosemide, European Pharmacopoeia (EP) Reference Standard

InChI key

ZZUFCTLCJUWOSV-UHFFFAOYSA-N

SMILES string

NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl

InChI

1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

grade

pharmaceutical primary standard

API family

furosemide

manufacturer/tradename

EDQM

mp

220 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... SLC12A1(6557)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
1287008BP547PHR1057
Furosemide European Pharmacopoeia (EP) Reference Standard

F0700000

Furosemide

Furosemide United States Pharmacopeia (USP) Reference Standard

USP

1287008

Furosemide

Furosemide British Pharmacopoeia (BP) Reference Standard

BP547

Furosemide

Furosemide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1057

Furosemide

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

BP

manufacturer/tradename

-

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

forensics and toxicology
pharmaceutical (small molecule)

API family

furosemide

API family

furosemide

API family

furosemide

API family

furosemide

mp

220 °C (dec.) (lit.)

mp

220 °C (dec.) (lit.)

mp

220 °C (dec.) (lit.)

mp

220 °C (dec.) (lit.)

Application

Furosemide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Inhibits ion co-transport in the kidney.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Case scenario: Hemodynamic management of postoperative acute kidney injury.
Matthieu Legrand et al.
Anesthesiology, 118(6), 1446-1454 (2013-04-06)
Maarten C van Loon et al.
Hearing research, 298, 17-26 (2013-01-31)
It is well known that spiral ganglion cells (SGCs) degenerate in hair-cell-depleted cochleas and that treatment with exogenous neurotrophins can prevent this degeneration. Several studies reported that, in addition, SGC size decreases after deafening and increases after neurotrophic treatment. The
Naoki Sato et al.
Circulation journal : official journal of the Japanese Circulation Society, 77(4), 944-951 (2013-03-19)
Hospitalized heart failure (HHF) is a critical issue in Japan. To improve its management and outcomes, the clinical features, in-hospital management, and outcomes should be analyzed to improve the guidelines for HHF. The acute decompensated heart failure syndromes (ATTEND) registry
F H Wilson et al.
Science (New York, N.Y.), 293(5532), 1107-1112 (2001-08-11)
Hypertension is a major public health problem of largely unknown cause. Here, we identify two genes causing pseudohypoaldosteronism type II, a Mendelian trait featuring hypertension, increased renal salt reabsorption, and impaired K+ and H+ excretion. Both genes encode members of
Christianne L Roumie et al.
Stroke, 46(2), 465-470 (2015-01-01)
We examined blood pressure 1 year after stroke discharge and its association with treatment intensification. We examined the systolic blood pressure (SBP) stratified by discharge SBP (≤140, 141-160, or >160 mm Hg) among a national cohort of Veterans discharged after

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica